 |
|
The Infrequency of Liver Function Testing in Patients Using Nonsteroidal Anti-inflammatory Drugs
Alexander M. Walker, MD, DrPH;
Edward A. Bortnichak, MPH, PhD;
Lee Lanza, MPH;
Robert A. Yood, MD
Arch Fam Med. 1995;4(1):24-29.
Abstract
| |
Objective
To describe the monitoring of liver function for patients using nonsteroidal anti-inflammatory drugs (NSAIDs), we reviewed the patterns of liver function testing in a medium-sized health maintenance organization.
Methods
We examined the interval between start of therapy and first performance of a liver function test during courses of therapy of the NSAIDs diclofenac sodium, naproxen and naproxen sodium, and piroxicam. For comparison, we also studied courses of lovastatin as a "positive control," in which the anticipated frequency of liver function testing was high.
Results
The frequency of liver function tests in patients using NSAIDs was generally low, although testing was more common in patients who used diclofenac. The probability of liver function testing was higher for patients treated in recent calendar years, for patients treated by rheumatologists, for patients who previously used NSAIDs, and for patients who had undergone a liver function test sometime in the 6 months preceding the onset of therapy.
Conclusion
Physicians ordered liver function tests less frequently than recommended, but the observed testing patterns appear rational in light of the very low reported frequency of serious hepatic disease in large, monitored populations of patients using NSAIDs.
Author Affiliations
From Epidemiology Resources Inc, Newton Lower Falls (Dr Walker and Ms Lanza), and the Department of Epidemiology, Harvard School of Public Health, Boston (Dr Walker), Mass; Ciba-Geigy Corp, Summit, NJ (Dr Bortnichak); and Fallon Clinic, Worcester, Mass (Dr Yood). Dr Bortnichak is now with Berlex Laboratories Inc, Wayne NJ.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Adherence to black box warnings for prescription medications in outpatients.
Lasser et al.
Arch Intern Med 2006;166:338-344.
ABSTRACT
| FULL TEXT
Liver Enzyme Monitoring in Patients Treated With Troglitazone
Graham et al.
JAMA 2001;286:831-833.
ABSTRACT
| FULL TEXT
|
